GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » Piotroski F-Score

Applied Genetic Technologies (Applied Genetic Technologies) Piotroski F-Score : 3 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Applied Genetic Technologies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Applied Genetic Technologies's Piotroski F-Score or its related term are showing as below:

AGTC' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 3

During the past 11 years, the highest Piotroski F-Score of Applied Genetic Technologies was 5. The lowest was 1. And the median was 3.


Applied Genetic Technologies Piotroski F-Score Historical Data

The historical data trend for Applied Genetic Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Genetic Technologies Piotroski F-Score Chart

Applied Genetic Technologies Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 1.00 1.00 3.00

Applied Genetic Technologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 2.00 4.00 3.00 3.00

Competitive Comparison of Applied Genetic Technologies's Piotroski F-Score

For the Biotechnology subindustry, Applied Genetic Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Genetic Technologies's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Applied Genetic Technologies's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Net Income was -19.144 + -14.294 + -18.386 + -18.41 = $-70.23 Mil.
Cash Flow from Operations was -17.557 + -13.997 + -18.258 + -16.037 = $-65.85 Mil.
Revenue was 0 + 0 + 0.325 + 0 = $0.33 Mil.
Gross Profit was 0 + 0 + 0.325 + 0 = $0.33 Mil.
Average Total Assets from the begining of this year (Sep21)
to the end of this year (Sep22) was
(110.411 + 92.37 + 87.191 + 66.684 + 57.333) / 5 = $82.7978 Mil.
Total Assets at the begining of this year (Sep21) was $110.41 Mil.
Long-Term Debt & Capital Lease Obligation was $9.34 Mil.
Total Current Assets was $37.24 Mil.
Total Current Liabilities was $26.60 Mil.
Net Income was -15.422 + -14.851 + -12.136 + -17.119 = $-59.53 Mil.

Revenue was 0 + 0 + 0.5 + 0 = $0.50 Mil.
Gross Profit was 0 + 0 + 0.5 + 0 = $0.50 Mil.
Average Total Assets from the begining of last year (Sep20)
to the end of last year (Sep21) was
(85.615 + 71.969 + 129.666 + 126.966 + 110.411) / 5 = $104.9254 Mil.
Total Assets at the begining of last year (Sep20) was $85.62 Mil.
Long-Term Debt & Capital Lease Obligation was $18.88 Mil.
Total Current Assets was $93.39 Mil.
Total Current Liabilities was $21.71 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Applied Genetic Technologies's current Net Income (TTM) was -70.23. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Applied Genetic Technologies's current Cash Flow from Operations (TTM) was -65.85. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep21)
=-70.234/110.411
=-0.63611416

ROA (Last Year)=Net Income/Total Assets (Sep20)
=-59.528/85.615
=-0.69529872

Applied Genetic Technologies's return on assets of this year was -0.63611416. Applied Genetic Technologies's return on assets of last year was -0.69529872. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Applied Genetic Technologies's current Net Income (TTM) was -70.23. Applied Genetic Technologies's current Cash Flow from Operations (TTM) was -65.85. ==> -65.85 > -70.23 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=9.342/82.7978
=0.11282908

Gearing (Last Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=18.877/104.9254
=0.17990877

Applied Genetic Technologies's gearing of this year was 0.11282908. Applied Genetic Technologies's gearing of last year was 0.17990877. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep22)=Total Current Assets/Total Current Liabilities
=37.239/26.604
=1.39975192

Current Ratio (Last Year: Sep21)=Total Current Assets/Total Current Liabilities
=93.386/21.709
=4.30171818

Applied Genetic Technologies's current ratio of this year was 1.39975192. Applied Genetic Technologies's current ratio of last year was 4.30171818. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Applied Genetic Technologies's number of shares in issue this year was 64.911. Applied Genetic Technologies's number of shares in issue last year was 42.823. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.325/0.325
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.5/0.5
=1

Applied Genetic Technologies's gross margin of this year was 1. Applied Genetic Technologies's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep21)
=0.325/110.411
=0.00294355

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep20)
=0.5/85.615
=0.0058401

Applied Genetic Technologies's asset turnover of this year was 0.00294355. Applied Genetic Technologies's asset turnover of last year was 0.0058401. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Applied Genetic Technologies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Applied Genetic Technologies  (NAS:AGTC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Applied Genetic Technologies Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Applied Genetic Technologies's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Traded in Other Exchanges
N/A
Address
14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Executives
Susan Schneider officer: Chief Medical Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber officer: Chief Financial Officer C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter officer: See Remarks 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds officer: Chief Accounting Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer director, officer: President and CEO C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay officer: General Counsel C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria officer: Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad director C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v. 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v. 10 percent owner C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex officer: General Counsel C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615